These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

904 related items for PubMed ID: 16551869

  • 41. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, Huber PE.
    Cancer Res; 2003 Jul 01; 63(13):3755-63. PubMed ID: 12839971
    [Abstract] [Full Text] [Related]

  • 42. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
    Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK.
    Clin Cancer Res; 2007 Jul 15; 13(14):4209-17. PubMed ID: 17634550
    [Abstract] [Full Text] [Related]

  • 43. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
    Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM.
    Cancer Res; 1999 Nov 01; 59(21):5412-6. PubMed ID: 10554007
    [Abstract] [Full Text] [Related]

  • 44. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S.
    J Surg Res; 2006 May 15; 132(2):208-13. PubMed ID: 16580691
    [Abstract] [Full Text] [Related]

  • 45. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK, Joe YA, Lee SK, Kim EK, O E, Kim HK, Oh BJ, Hong SH, Hong YK.
    Cancer Lett; 2010 Feb 28; 288(2):251-60. PubMed ID: 19664879
    [Abstract] [Full Text] [Related]

  • 46. SU6668, a multitargeted angiogenesis inhibitor.
    Hoekman K.
    Cancer J; 2001 Feb 28; 7 Suppl 3():S134-8. PubMed ID: 11779084
    [Abstract] [Full Text] [Related]

  • 47. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.
    Oncogene; 2005 Jan 27; 24(5):790-800. PubMed ID: 15592523
    [Abstract] [Full Text] [Related]

  • 48. Extracellular HSP70 blocks CD40L-induced apoptosis and tubular formation in endothelial cells.
    Futagami S, Hiratsuka T, Shindo T, Hamamoto T, Horie A, Ueki N, Kusunoki M, Gudis K, Miyake K, Tsukui T, Sakamoto C.
    J Gastroenterol Hepatol; 2008 Dec 27; 23 Suppl 2():S222-8. PubMed ID: 19120902
    [Abstract] [Full Text] [Related]

  • 49. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
    Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'reilly MS, Fidler IJ, Herbst RS.
    Clin Cancer Res; 2004 Dec 15; 10(24):8613-9. PubMed ID: 15623645
    [Abstract] [Full Text] [Related]

  • 50. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
    Shibata A, Nakagawa K, Sookwong P, Tsuzuki T, Oikawa S, Miyazawa T.
    Biochem Pharmacol; 2008 Aug 01; 76(3):330-9. PubMed ID: 18599020
    [Abstract] [Full Text] [Related]

  • 51. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, Glanzmann C, Bodis S, Pruschy M.
    Br J Cancer; 2001 Dec 14; 85(12):2010-6. PubMed ID: 11747347
    [Abstract] [Full Text] [Related]

  • 52. TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis.
    Yorozuya K, Kubota T, Watanabe M, Hasegawa H, Ozawa S, Kitajima M, Chikahisa LM, Yamada Y.
    Oncol Rep; 2005 Sep 14; 14(3):677-82. PubMed ID: 16077974
    [Abstract] [Full Text] [Related]

  • 53. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
    Sini P, Wyder L, Schnell C, O'Reilly T, Littlewood A, Brandt R, Hynes NE, Wood J.
    Clin Cancer Res; 2005 Jun 15; 11(12):4521-32. PubMed ID: 15958638
    [Abstract] [Full Text] [Related]

  • 54. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
    Wong TW, Lee FY, Emanuel S, Fairchild C, Fargnoli J, Fink B, Gavai A, Hammell A, Henley B, Hilt C, Hunt JT, Krishnan B, Kukral D, Lewin A, Malone H, Norris D, Oppenheimer S, Vite G, Yu C.
    Clin Cancer Res; 2011 Jun 15; 17(12):4031-41. PubMed ID: 21531814
    [Abstract] [Full Text] [Related]

  • 55. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B.
    Cancer Chemother Pharmacol; 2005 Dec 15; 56(6):569-77. PubMed ID: 16001166
    [Abstract] [Full Text] [Related]

  • 56. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA, Robinson C, Angeles T, Wilkinson J, Clapper ML.
    Clin Cancer Res; 2002 Jan 15; 8(1):267-74. PubMed ID: 11801568
    [Abstract] [Full Text] [Related]

  • 57. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1630-8. PubMed ID: 16533791
    [Abstract] [Full Text] [Related]

  • 58. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
    Tai KF, Chen PJ, Chen DS, Hwang LH.
    J Gene Med; 2003 May 01; 5(5):386-98. PubMed ID: 12731087
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 46.